Annual report [Section 13 and 15(d), not S-K Item 405]

SHAREHOLDERS' EQUITY

v3.26.3
SHAREHOLDERS' EQUITY
12 Months Ended
Aug. 31, 2026
SHAREHOLDERS' EQUITY  
SHAREHOLDERS' EQUITY

NOTE 8 – SHAREHOLDERS’ EQUITY

Preferred Stock

The Company’s non-voting Series B Preferred Stock has a preference in liquidation of $1.00 per share less any dividends previously paid. Additionally, the Series B Preferred Stock is redeemable at the discretion of the Company for $1.00 per share less any dividends previously paid. In the event the proceeds from the sale or disposition of Export Water rights exceed $36.0 million the Series B Preferred Shareholders will receive the next $0.4 million of proceeds in the form of a dividend. The terms of the Series B Preferred Stock prohibit payment of dividends on common stock unless all dividends accrued on the Series B Preferred Stock have been paid. To date, no dividends have been accrued as this contingency has not been met.

Share Repurchase Program

On November 2, 2022, the Company’s Board of Directors authorized the repurchase of up to 200,000 shares of the Company’s common stock. The program has no expiration date. During fiscal 2026 and 2025, the Company repurchased 26,100 and 35,500 shares for $0.3 million and $0.4 million, respectively, and retired the repurchased shares. At August 31, 2026, 78,474 shares remained available for repurchase under the program.

Equity Compensation Plan

The Company maintains the 2024 Equity Incentive Plan (2024 Equity Plan), which was approved by shareholders in January 2024 and became effective January 17, 2024.  Executives, eligible employees, consultants, and non-employee directors are eligible to receive options and stock grants pursuant to the 2024 Equity Plan. Options to purchase shares of stock and restricted stock awards can be granted with exercise prices, vesting conditions and other performance criteria determined by the Compensation Committee of the Company’s Board of Directors. The Company has reserved 2.0 million shares of common stock for issuance under the 2024 Equity Plan.  As of August 31, 2026, 89,175 shares had been issued and there were 1,910,825 shares available for grant under the 2024 Equity Plan. Prior to the effective date of the 2024 Equity Plan, the Company granted stock awards to eligible participants under its 2014 Equity Incentive Plan (2014 Equity Plan), which expired April 12, 2024. As of August 31, 2026, restricted stock awards and awards to purchase 577,000 shares of the Company’s common stock have been made under the 2014 Equity Plan, of which 422,500 remain outstanding. No additional awards may be granted pursuant to the 2014 Equity Plan.

The Company estimates the fair value of share-based payment awards on the date of grant using the Black-Scholes option-pricing model (Black-Scholes model). Using the Black-Scholes model, the value of the portion of the award that is ultimately expected to vest is recognized as a period expense over the requisite service period in the consolidated statements of income. Option forfeitures are to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company does not expect any forfeiture of its options; therefore, the compensation expense has not been reduced for estimated forfeitures. No options expired in either of the years ended August 31, 2026 and 2025. The Company attributes the value of share-based compensation to expense using the straight-line single option method for all options granted.

The Company’s determination of the estimated fair value of share-based payment awards on the date of grant is affected by the following variables and assumptions:

● The grant date exercise price – is the closing market price of the Company’s common stock on the date of grant;
● Estimated dividend rates – based on historical and anticipated dividends over the life of the option;
● Life of the option – based on historical experience, including actual and projected employee stock option exercise, option grants have lives of between five and ten years;
● Risk-free interest rates – with maturities that approximate the expected life of the options granted;
● Calculated stock price volatility – calculated over the expected life of the options granted, which is calculated based on the weekly closing price of the Company’s common stock over a period equal to the expected life of the option.

The assumptions used in the fair value calculations using the Black-Scholes model are as follows:

​

​

​

​

​

​

​

​

​

  ​ ​ ​

August 31, 2026

  ​ ​ ​

August 31, 2025

 

Expected term (years)

  ​ ​ ​

​

6.00

  ​ ​ ​

​

—

​

Risk-free interest rate

 

​

4.10

%  

​

—

%

Expected volatility

 

​

36.61

%  

​

—

%

Expected dividend yield

 

​

—

%  

​

—

%

Weighted average grant-date fair value

​

$

4.59

​

$

—

​

​

For the year ended August 31, 2026, the Company granted options to purchase 30,000 shares of common stock with an exercise price of $10.75 per share and a grant date fair value of $4.59 per share, which expire ten years from the date of grant. In addition, seven non-employee Board members were granted an aggregate of 18,571 unrestricted shares of common stock. The fair market value of the unrestricted shares for share-based compensation expense is equal to the closing price of the Company’s common stock on the date of grant of $11.31. The Company also issued an employee 10,000 unrestricted shares of common stock with the fair market value of the shares for share-based compensation expense equal to the closing price of the Company’s common stock on the date of grant of $11.43. Stock-based compensation expense includes $0.3 million of expense related to these unrestricted stock grants, which were fully expensed at the date of grant because no vesting requirements existed. The Company issued four employees a total of 5,000 shares of restricted stock. These shares vested 20% on the grant date, and 20% will vest on each anniversary of the grant date for four years subject to continued employment. The shares are eligible to vote and participate in any dividend or stock splits approved by the Company. Additionally, during the year ended August 31, 2026, 1,200 shares of restricted stock were surrendered upon the termination of employment of one former employee.  

For the year ended August 31, 2025, the Company granted no stock options. In addition, six non-employee Board members were each granted 2,566 unrestricted shares of common stock. The fair market value of the unrestricted shares for share-based compensation expense is equal to the closing price of the Company’s common stock on the date of grants of $11.69. Stock-based compensation expense includes $0.2 million of expense related to these unrestricted stock grants. The unrestricted stock grants were fully expensed at the date of the grant because no vesting requirements existed for the unrestricted stock grants.

During the years ended August 31, 2026 and 2025, 67,000 and 35,000 options were exercised. Of the options exercised in 2026, 10,000 were exercised for cash proceeds of less than $0.1 million and 57,000 were net settled, meaning the optionee did not pay cash for the options but instead received the number of shares equal to the difference between the exercise price and the market price on the date of exercise, resulting in 9,210 shares being issued and 47,790 options being cancelled. The options exercised in 2025 were net settled, resulting in 13,815 shares being issued and 21,185 options being cancelled in settlement of shares issued.  

The following table summarizes the combined stock option activity for the 2014 Equity Plan and 2024 Equity Plan for the years ended August 31, 2026 and August 31, 2025:

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Number of Options

  ​ ​ ​

Weighted Average Exercise Price

  ​ ​ ​

Weighted Average Remaining Contractual Term

  ​ ​ ​

Approximate Aggregate Intrinsic Value
(in thousands)

Outstanding at August 31, 2025

​

489,500

​

$

9.52

​

3.8

​

$

616

Granted

 

30,000

​

​

10.75

​

​

​

​

​

Exercised

 

(67,000)

​

​

8.98

​

​

​

​

​

Forfeited / Expired

​

—

​

​

—

​

​

​

​

​

Outstanding at August 31, 2026

 

452,500

​

​

9.69

​

3.3

​

​

813

Options exercisable at August 31, 2026

 

422,500

​

$

9.61

​

2.9

​

$

802

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Outstanding at August 31, 2024

 

524,500

​

$

9.42

​

4.7

​

$

877

Granted

 

—

​

​

—

​

​

​

​

​

Net settlement exercised

 

(35,000)

​

​

7.89

​

​

​

​

​

Forfeited / Expired

​

—

​

​

—

​

​

​

​

​

Outstanding at August 31, 2025

 

489,500

​

$

9.52

​

3.8

​

$

616

​

The following table summarizes the activity and value of non-vested options as of and for the years ended August 31, 2026 and August 31, 2025:

​

​

​

​

​

​

​

  ​ ​ ​

Number of Options

  ​ ​ ​

Weighted Average Grant Date Fair Value

Non-vested options outstanding at August 31, 2025

​

17,000

​

$

3.93

Granted

 

30,000

​

​

4.59

Vested

 

(17,000)

​

​

3.93

Forfeited / Expired

 

—

​

​

—

Non-vested options outstanding at August 31, 2026

 

30,000

​

$

4.59

​

​

​

​

​

​

Non-vested options outstanding at August 31, 2024

 

59,000

​

$

4.45

Granted

 

—

​

​

—

Vested

 

(42,000)

​

​

4.66

Forfeited

​

—

​

​

—

Non-vested options outstanding at August 31, 2025

 

17,000

​

$

3.93

​

All non-vested options are expected to vest. For the years ended August 31, 2026 and 2025, the total fair value of options that vested during the year was $0.1 million and $0.2 million, respectively. During the year ended August 31, 2026, the Company granted options to purchase 30,000 shares; no options were granted during the year ended August 31, 2025.

For the years ended August 31, 2026 and 2025, share-based compensation expense was $0.4 million and $0.3 million, respectively.

As of August 31, 2026, the Company had unrecognized share-based compensation expense totaling $0.2 million relating to non-vested options and restricted stock that are expected to vest over a weighted average period of 2.2 years.